Thus, PKCθ-deficient donor T cells demonstrated reduced ability to induce disease in MHC-mismatched hosts (using TCD-BMT GVHD models [29,30], fitting to impaired in vivo proliferation in allogenic settings at day 3 or 4 after ACT [29,31]. This evidence concerns the gene PRRT2 and graft versus host disease.